Company intelligence / Profile preview
Revere Pharmaceuticals
Arlington, Massachusetts, United Statesreverepharma.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Revere Pharmaceuticals is developing a pipeline of first-in-class small molecule inhibitors targeting Rac1 and related Rho GTPases for cancers with high unmet need, such as colorectal cancer and non-small cell lung cancer. Their lead program has reached the IND application stage; others are preclinical. No clinical results have been reported as of March 2025.
- Therapeutic areas
- Oncology
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
Beyond the preview
Go deeper on Revere Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Revere Pharmaceuticals.